The Challenge
Advances in AI, single cell multiomics, and large-scale datasets are transforming drug discovery, enabling rapid identification of targets, biomarkers, and therapeutic opportunities.
However, a key bottleneck remains: validating these discoveries in a human-relevant system before clinical development.
Current preclinical models often fail to capture human immune complexity, leading to high development risk and limited predictive power. 

Our Solution
We developed a personalized in vitro platform that recreates key aspects of the human immune system.
It integrates vascularized human tissues with autologous immune cells, endothelial cells, and serum from the same donor, forming a physiologically relevant multi-organ environment.
Unlike conventional systems, it enables dynamic interactions within a personalized human biological context. 

Key Differentiators
> Interconnected vascularized human tissues
> Autologous immune cells
> Integrated endothelial compartment
> Adaptive immune-response capability
> Personalized multi-organ system
> Longitudinal immune monitoring 

Applications
> Target Validation
    Assess whether target modulation drives expected immune and tissue responses.
> Drug Screening & Prioritization
    Evaluate efficacy, mechanism, immune activation, and toxicity.
> Biomarker Validation
    Differentiate functional biomarkers from correlative ones.
> Treatment Response Prediction
    Test therapies in patient-derived systems pre-clinically.
> Immunotherapy Development
    Optimize checkpoint inhibitors, cell therapies, and immune modulators. 

Strategic Value
> Improve translational predictability
> Reduce reliance on animal models
> Accelerate development timelines
> Support better go/no-go decisions
> Generate longitudinal human immune data
> Enable richer datasets for AI-driven discovery 

Vision
> As drug discovery becomes more data-driven, human-relevant validation systems are essential.
> Our platform bridges this gap with a personalized, multi-organ immune model for more predictive and actionable development. 

IP Status
International patent application filed (PCT/IL2025/051032).